Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 28:S0953-6205(25)00255-9.
doi: 10.1016/j.ejim.2025.06.016. Online ahead of print.

Incidence and prevalence of systemic lupus erythematosus across Italian referral centers and its clinical burden in terms of disease severity, treatment and hospitalization: The ESCULAPIO study

Irene Mattioli  1 , Michela Gasparotto  2 , Alberto Bergamini  3 , Alessandra Bortoluzzi  4 , Francesco Ciccia  5 , Fabrizio Conti  6 , Maria Antonietta D'agostino  7 , Micaela Fredi  8 , Roberto Giacomelli  9 , Florenzo Iannone  10 , Ilaria Mormile  11 , Matteo Piga  12 , Luca Quartuccio  13 , Gian Domenico Sebastiani  14 , Chiara Tani  15 , Angelo Vacca  16 , Margherita Zen  17 , Alessandra Bettiol  18 , Giacomo Emmi  19 ; ESCULAPIO consortium
Collaborators, Affiliations
Free article

Incidence and prevalence of systemic lupus erythematosus across Italian referral centers and its clinical burden in terms of disease severity, treatment and hospitalization: The ESCULAPIO study

Irene Mattioli et al. Eur J Intern Med. .
Free article

Abstract

Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multiorgan involvement. Limited data from specialized referral centers are available at national level. This study assessed epidemiologic, clinical, therapeutic features and hospitalization burden of SLE through data from tertiary Italian referral centers.

Methods: A cross-sectional study was conducted across 16 SLE referral centers in 10 districts of the North, Center and South of Italy. Only patient resident in the districts of interest were included. Demographic, clinical, and therapeutic features were collected. Prevalence and incidence estimates were calculated using data from the National Institute of Statistics.

Results: 2.031 SLE patients were included. In January 2024, the estimated prevalence of SLE was 15.3 cases/100.000 individuals, varying from 11.3 (South and Islands), 13.1 (Center), and 25.3 (North) cases/100.000 individuals. Incidence showed a decreasing trend, from 0.43 cases/100.000 individuals in 2019 to 0.29 in 2022. Most patients were female (89.5 %), with a mean age at diagnosis of 35.4 years. Musculoskeletal (70.7 %) and mucocutaneous (60.2 %) were the most common manifestations. Disease severity was classified as mild (33.2 %), moderate (33.0 %) and severe (33.8 %). 38.6 % patients had a relapsing-remitting course, 13.0 % were chronic-active, and 48.4 % long-quiescent. High reliance on corticosteroids (85 %) and underutilization of biologic DMARDs (26 %) emerged. 55.4 % of patients experienced hospitalizations for any cause and 33.4 % for SLE relapses.

Conclusion: This study provides insights into epidemiological, clinical, and therapeutic features of SLE across referral centers highlighting significant regional disparities and emphasizing the need to increasingly align with EULAR recommendations even in highly qualified centers.

Keywords: Belimumab; Disease severity; Epidemiology; Hospitalization; Rituximab; Systemic lupus erythematosus.

PubMed Disclaimer

LinkOut - more resources